Clinical trial
A Phase IIa, Dose-Escalation Followed by Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
NCT06147986 is registered in ClinicalTrials.gov with Ever Supreme Bio Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Dose-Escalation Followed by Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
- Lead sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 24, 2023
- Completion date
- June 24, 2027
- Enrollment
- 41 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.